Gilead HCV Sales Decline In US, But Offset By Global Growth

Strong sales growth continues almost unabated at Gilead Sciences Inc., but the virology powerhouse reported that domestic sales for its hepatitis C drugs actually decreased by 26% year-over-year during the fourth quarter.